HRMY vs. CPRX

Last updated Apr 1, 2026

Compare and contrast key facts about Harmony Biosciences Holdings, Inc. (HRMY) and Catalyst Pharmaceuticals, Inc. (CPRX).

Performance

HRMY vs. CPRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Harmony Biosciences Holdings, Inc. (HRMY) and Catalyst Pharmaceuticals, Inc. (CPRX). The values are adjusted to include any dividend payments, if applicable.

HRMY vs. CPRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
HRMY Harmony Biosciences Holdings, Inc.	-25.15%	8.75%	6.53%	-41.38%	29.22%	17.95%	-2.32%
CPRX Catalyst Pharmaceuticals, Inc.	6.08%	11.84%	24.15%	-9.62%	174.74%	102.69%	-7.73%

Fundamentals

Market Cap HRMY : $1.64B CPRX : $3.15B
EPS HRMY : $3.33 CPRX : $1.68
PE Ratio HRMY : 8.41 CPRX : 14.71
PEG Ratio HRMY : 0.08 CPRX : 0.26
PS Ratio HRMY : 1.89 CPRX : 5.35
PB Ratio HRMY : 1.89 CPRX : 3.30
Total Revenue (TTM) HRMY : $868.45M CPRX : $588.99M
Gross Profit (TTM) HRMY : $670.11M CPRX : $726.82M
EBITDA (TTM) HRMY : $238.25M CPRX : $257.78M

Returns By Period

In the year-to-date period, HRMY achieves a -25.15% return, which is significantly lower than CPRX's 6.08% return.

HRMY

• 1D: 4.13%
• 1M: -1.86%
• YTD: -25.15%
• 6M: 1.63%
• 1Y: -15.61%
• 3Y*: -4.98%
• 5Y*: -2.68%
• 10Y*: —

CPRX

• 1D: 4.12%
• 1M: 7.28%
• YTD: 6.08%
• 6M: 25.69%
• 1Y: 2.10%
• 3Y*: 14.30%
• 5Y*: 40.58%
• 10Y*: 35.35%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

HRMY vs. CPRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HRMY

HRMY Risk / Return Rank: 25
HRMY Sharpe Ratio Rank: 25
HRMY Sortino Ratio Rank: 25
HRMY Omega Ratio Rank: 24
HRMY Calmar Ratio Rank: 28
HRMY Martin Ratio Rank: 25

CPRX

CPRX Risk / Return Rank: 41
CPRX Sharpe Ratio Rank: 44
CPRX Sortino Ratio Rank: 38
CPRX Omega Ratio Rank: 37
CPRX Calmar Ratio Rank: 42
CPRX Martin Ratio Rank: 41

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HRMY vs. CPRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Harmony Biosciences Holdings, Inc. (HRMY) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	HRMY	CPRX	Difference
Sharpe ratio Return per unit of total volatility	-0.37	0.06	-0.43
Sortino ratio Return per unit of downside risk	-0.24	0.32	-0.57
Omega ratio Gain probability vs. loss probability	0.96	1.04	-0.08
Calmar ratio Return relative to maximum drawdown	-0.45	0.01	-0.46
Martin ratio Return relative to average drawdown	-0.98	0.02	-1.00
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

HRMY vs. CPRX - Sharpe Ratio Comparison

The current HRMY Sharpe Ratio is -0.37, which is lower than the CPRX Sharpe Ratio of 0.06. The chart below compares the historical Sharpe Ratios of HRMY and CPRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	HRMY	CPRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.37	0.06	-0.43
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.05	0.85	-0.90
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.56	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.09	0.08	-0.17

Correlation

The correlation between HRMY and CPRX is 0.35, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

HRMY vs. CPRX - Dividend Comparison

Neither HRMY nor CPRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

HRMY vs. CPRX - Drawdown Comparison

The maximum HRMY drawdown since its inception was -68.48%, smaller than the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for HRMY and CPRX.

Drawdown Indicators

	HRMY	CPRX	Difference
Max Drawdown Largest peak-to-trough decline	-68.48%	-94.25%	+25.77%
Max Drawdown (1Y) Largest decline over 1 year	-34.49%	-27.29%	-7.20%
Max Drawdown (5Y) Largest decline over 5 years	-68.48%	-45.37%	-23.11%
Max Drawdown (10Y) Largest decline over 10 years	—	-64.87%	—
Current Drawdown Current decline from peak	-54.01%	-5.89%	-48.12%
Average Drawdown Average peak-to-trough decline	-34.74%	-52.51%	+17.77%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.95%	15.10%	+0.85%

Volatility

HRMY vs. CPRX - Volatility Comparison

The current volatility for Harmony Biosciences Holdings, Inc. (HRMY) is 8.18%, while Catalyst Pharmaceuticals, Inc. (CPRX) has a volatility of 10.39%. This indicates that HRMY experiences smaller price fluctuations and is considered to be less risky than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	HRMY	CPRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.18%	10.39%	-2.21%
Volatility (6M) Calculated over the trailing 6-month period	31.02%	23.71%	+7.31%
Volatility (1Y) Calculated over the trailing 1-year period	41.98%	34.96%	+7.02%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	50.63%	48.24%	+2.39%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	52.83%	62.81%	-9.98%

Financials